128 related articles for article (PubMed ID: 2478560)
1. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer.
Porzsolt F; Otto AM; Trauschel B; Buck C; Wawer AW; Schönenberger H
J Cancer Res Clin Oncol; 1989; 115(5):465-9. PubMed ID: 2478560
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.
Lindner DJ; Borden EC
J Interferon Cytokine Res; 1997 Nov; 17(11):681-93. PubMed ID: 9402106
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells.
Lama G; Angelucci C; Recchia F; Sica G
Cancer Lett; 1996 Feb; 100(1-2):181-9. PubMed ID: 8620440
[TBL] [Abstract][Full Text] [Related]
4. Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.
Goldstein D; Bushmeyer SM; Witt PL; Jordan VC; Borden EC
Cancer Res; 1989 May; 49(10):2698-702. PubMed ID: 2469536
[TBL] [Abstract][Full Text] [Related]
5. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of cytotoxicity using combinations of interferons (types I and II), tumor necrosis factor-alpha, and tamoxifen in MCF-7 cells.
Tiwari RK; Wong GY; Liu J; Miller D; Osborne MP
Cancer Lett; 1991 Dec; 61(1):45-52. PubMed ID: 1764697
[TBL] [Abstract][Full Text] [Related]
7. Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.
Otto AM
J Cancer Res Clin Oncol; 1994; 120(5):286-92. PubMed ID: 7510292
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.
Lindner DJ; Kolla V; Kalvakolanu DV; Borden EC
Mol Cell Biochem; 1997 Feb; 167(1-2):169-77. PubMed ID: 9059994
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and tranilast show a synergistic effect against breast cancer in vitro.
Darakhshan S; Ghanbari A; Gholami Rad F; Bidmeshki Pour A
Bratisl Lek Listy; 2015; 116(1):69-73. PubMed ID: 25666966
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.
Di Monaco M; Brignardello E; Leonardi L; Gatto V; Boccuzzi G
J Cancer Res Clin Oncol; 1995; 121(12):710-4. PubMed ID: 7499441
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro.
Tanos V; Brzezinski A; Drize O; Strauss N; Peretz T
Eur J Obstet Gynecol Reprod Biol; 2002 May; 102(2):188-94. PubMed ID: 11950489
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of nitric oxide production by droloxifene and toremifene in human breast cancer cells.
Martin JH; Symonds A; Chohan S
Oncol Rep; 2003; 10(4):979-84. PubMed ID: 12792756
[TBL] [Abstract][Full Text] [Related]
13. Interaction of retinoic acid and interferon-alpha in breast cancer cell lines.
Widschwendter M; Daxenbichler G; Bachmair F; Müller E; Zeimet AG; Windbichler G; Uhl-Steidl M; Lang T; Marth C
Anticancer Res; 1996; 16(1):369-74. PubMed ID: 8615638
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells.
de Vincenzo R; Scambia G; Benedetti Panici P; Bonanno G; Ercoli A; Fattorossi A; Pernisco S; Isola G; Mancuso S
Ann N Y Acad Sci; 1996 Apr; 784():517-20. PubMed ID: 8651609
[No Abstract] [Full Text] [Related]
15. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M
Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
[TBL] [Abstract][Full Text] [Related]
17. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells.
Cover CM; Hsieh SJ; Cram EJ; Hong C; Riby JE; Bjeldanes LF; Firestone GL
Cancer Res; 1999 Mar; 59(6):1244-51. PubMed ID: 10096555
[TBL] [Abstract][Full Text] [Related]
18. Additive and synergistic antitumor effects with toremifene and interferons.
Kangas L; Cantell K; Schellekens H
J Steroid Biochem; 1990 Jun; 36(3):259-62. PubMed ID: 2142249
[TBL] [Abstract][Full Text] [Related]
19. Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer.
Heinonen E; Alanko A; Gröhn P; Rissanen P
Breast Cancer Res Treat; 1985; 5(1):75-80. PubMed ID: 3978249
[TBL] [Abstract][Full Text] [Related]
20. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
